Literature DB >> 12909228

Radiotherapy in the management of giant cell tumor of bone.

Jimmy J Caudell1, Matthew T Ballo, Gunar K Zagars, Valerae O Lewis, Kristin L Weber, Patrick P Lin, Rex A Marco, Adel K El-Naggar, Robert S Benjamin, Alan W Yasko.   

Abstract

PURPOSE: To evaluate the outcomes of patients with giant cell tumor of bone (GCTB) treated with radiotherapy (RT) with or without surgical resection. METHODS AND MATERIALS: We performed a retrospective review of the records from 25 consecutive patients with pathologically confirmed GCTB who had undergone RT between 1956 and 2000.
RESULTS: Patients ranged in age from 11 to 69 years (median 32); 16 were female and 9 were male. The anatomic distribution of lesions was as follows: cervical spine, 3; temporal bone, 1; thoracic or lumbar spine, 9; sacrum, 8; ilium, 1, and humerus, radius, and thumb metacarpal, 1 each. Tumors ranged in size from 2 to 20 cm (median 9.5) at their maximal dimension. Thirteen patients had been referred for RT for primary GCTB and 12 had been referred with locally recurrent disease after having undergone one or more other treatments. Fourteen patients had undergone RT for gross disease, and the remaining 11 had been treated with RT after gross total resection. In 10 of these 11 patients, the treatment margins were positive or uncertain. Radiation doses ranged from 25 to 65 Gy (median 46). At a median follow-up of 8.8 years (range 0.67-34), 7 patients had developed isolated local recurrence, 2 had developed isolated distant recurrence, and 3 had developed both. The actuarial 5-year overall and disease-free survival rate was 91% and 58%, respectively, and the actuarial 5-year local control and distant metastasis-free survival rate was 62% and 81%, respectively. Univariate analysis suggested that treatment for recurrent disease correlated with a lower disease-free survival rate (83% vs. 33%, p = 0.06), distant metastasis-free survival rate (100% vs. 64%, p = 0.08), and local control rate (83% vs. 42%, p = 0.08) at 5 years. Of the 12 cases of recurrence, 7 were ultimately successfully treated with additional salvage therapy. In 4 of these patients, salvage therapy included interferon-alpha 2b.
CONCLUSION: RT should be considered an adjuvant to surgery or as alternative therapy in cases of GCTB that are unresectable or in which excision would result in substantial functional deficits. When RT is used as primary therapy, the rate of local control seems to be satisfactory. In heavily pretreated patients, however, RT delivered as it was in this series can result in poor local control, and alternative therapies should be considered.

Entities:  

Mesh:

Year:  2003        PMID: 12909228     DOI: 10.1016/s0360-3016(03)00416-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  48 in total

1.  Giant cell tumor of the fifth lumbar vertebra with a three-year follow-up: case report and review of the literature.

Authors:  Michael Athanassacopoulos; Georgios K Triantafyllopoulos; Spyridon G Pneumaticos
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-03-25

2.  A 20-year-old woman with a painful swollen left thumb.

Authors:  S K Tiwary; M K Singh; R C Shukla; M Pandey; V K Shukla
Journal:  Postgrad Med J       Date:  2006-10       Impact factor: 2.401

Review 3.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

Review 4.  Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.

Authors:  Christopher Martin; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2010

5.  Image-guided multilevel vertebral osteotomies for en bloc resection of giant cell tumor of the thoracic spine: case report and description of operative technique.

Authors:  Sheila M Smitherman; Claudio E Tatsui; Ganesh Rao; Garrett Walsh; Laurence D Rhines
Journal:  Eur Spine J       Date:  2010-01-13       Impact factor: 3.134

Review 6.  Multidisciplinary management of primary tumors of the vertebral column.

Authors:  Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2009-06-23

7.  Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.

Authors:  Noah Federman; Earl W Brien; Vivek Narasimhan; Sarah M Dry; Monish Sodhi; Sant P Chawla
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

8.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

9.  The rare case of giant cell tumor occuring in the axial skeleton after 15 years of follow-up: Case report.

Authors:  Ye-Soo Park; Jin Kyu Lee; Seung-Wook Baek; Chan-Kum Park
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

10.  A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases.

Authors:  Ira J Miller; Alan Blank; Suellen M Yin; Allison McNickle; Robert Gray; Steven Gitelis
Journal:  Diagn Pathol       Date:  2010-09-22       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.